Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Bevacizumab (Avastin), Erlotinib (Tarceva), and Imatinib (Gleevec) in the Treatment of Patients With Advanced Renal Cell Carcinoma

NCT00193258 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT00193258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00193258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Bevacizumab (Avastin), Erlotinib (Tarceva), and Imatinib (Gleevec) in the Treatment of Patients With Advanced Renal Cell Carcinoma
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2004
Completion date
August 31, 2011
Enrollment
94 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma